Skip to main content
TipRanks
Go Ultimate75% OFF

Ryvu Therapeutics SA (0RKT) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Ryvu Therapeutics SA has a market cap or net worth of PLN 390.27M. The enterprise value is PLN 381.76M.

Market Cap
PLN 390.27M
Enterprise Value
PLN 381.76M

Share Statistics

Ryvu Therapeutics SA has 23,120,148 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
23,120,148
Owned by Insiders
―
Owned by Institutions
0.02%

Financial Efficiency

Ryvu Therapeutics SA’s return on equity (ROE) is -1.88 and return on invested capital (ROIC) is -74.78%.

Return on Equity (ROE)
-1.88
Return on Assets (ROA)
-0.45
Return on Invested Capital (ROIC)
-74.78%
Return on Capital Employed (ROCE)
-0.75
Revenue Per Employee
273.04K
Profits Per Employee
-443.99K
Employee Count
228
Asset Turnover
0.28
Inventory Turnover
134.30

Valuation Ratios

The current PE Ratio of Ryvu Therapeutics SA is -5.93. Ryvu Therapeutics SA’s PEG ratio is -0.08.

PE Ratio
-5.93
PS Ratio
5.96
PB Ratio
39.92
Price to FCF
-4.61
Price to Operating Cash Flow
-4.97
PEG Ratio
-0.08

Income Statement

In the last 12 months, Ryvu Therapeutics SA had revenue of 62.25M and earned -101.23M in profits. Earnings per share was -4.38.

Revenue
62.25M
Gross Profit
-117.03M
Operating Income
-122.15M
Pretax Income
-101.14M
Net Income
-101.23M
EBITDA
-112.71M
Earnings Per Share (EPS)
-4.38

Cash Flow

In the last 12 months, operating cash flow was -75.29M and capital expenditures -5.87M, giving a free cash flow of -81.16M billion.

Operating Cash Flow
-75.29M
Free Cash Flow
-81.16M
Free Cash Flow per Share
-3.51

Dividends & Yields

Ryvu Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-21.70%
Earnings Yield
-16.67%

Stock Price Statistics

Beta
0.86
52-Week Price Change
0.00%
50-Day Moving Average
30.25
200-Day Moving Average
30.25
Relative Strength Index (RSI)
―
Average Volume (3m)
―

Important Dates

Ryvu Therapeutics SA upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 16, 2027
Ex-Dividend Date
―

Financial Position

Ryvu Therapeutics SA as a current ratio of 2.26, with Debt / Equity ratio of 133.22%

Current Ratio
2.26
Quick Ratio
2.24
Debt to Market Cap
0.11
Net Debt to EBITDA
-0.11
Interest Coverage Ratio
-13.88

Taxes

In the past 12 months, Ryvu Therapeutics SA has paid 88.00K in taxes.

Income Tax
88.00K
Effective Tax Rate
-0.00

Enterprise Valuation

Ryvu Therapeutics SA EV to EBITDA ratio is -7.78, with an EV/FCF ratio of -5.09.

EV to Sales
6.58
EV to EBITDA
-7.78
EV to Free Cash Flow
-5.09
EV to Operating Cash Flow
-5.49

Balance Sheet

Ryvu Therapeutics SA has PLN 57.55M in cash and marketable securities with PLN 77.72M in debt, giving a net cash position of -PLN 20.16M billion.

Cash & Marketable Securities
PLN 57.55M
Total Debt
PLN 77.72M
Net Cash
-PLN 20.16M
Net Cash Per Share
-PLN 0.87
Tangible Book Value Per Share
PLN 0.92

Margins

Gross margin is -25.71%, with operating margin of -109.97%, and net profit margin of -99.33%.

Gross Margin
-25.71%
Operating Margin
-109.97%
Pretax Margin
-98.59%
Net Profit Margin
-99.33%
EBITDA Margin
-84.66%
EBIT Margin
-97.13%

Analyst Forecast

The average price target for Ryvu Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
-10.07%
EPS Growth Forecast
47.47%